Skip to main content

Rapamycin

BML-A275

126 citations

  • BML-A275-0005   —   5 mg
    $150.00
  • BML-A275-0025   —   25 mg
    $347.00
  • Antibiotic with immunosuppressant and anti-cancer properties
  • Commonly used to study autophagy in a variety of cells
  • Highly cited

Rapamycin is a macrocyclic-triene antibiotic with potent immunosuppressant activity. Rapamycin forms a complex with FKBP12 that binds to an effector, thus inhibiting IL-2 and other growth promoting lymphokines. The effectors were identified as FRAP (FKBP12 rapamycin-associated protein) and RAFT1 (rapamycin and KFBP12 target). Rapamycin/FKBP complex does not inhibit FRAP PI 4-kinase activity, but does inhibit FRAP autophosphorylation. Rapamycin induces inhibition of p70s6k, p33cdk2 and p34cdc2. Rapamycin selectively blocks signaling leading to the activation of p70/85 S6 kinase. Rapamycin complexed with FKBP12 binds to and inhibits the activity of the mammalian target of rapamycin (mTOR) complex 1 (mTORC1). Rapamycin can inhibit cell growth, enhance apoptosis, and activates autophagy in a variety of cell types.

Shipping: Available products typically ship within 24/48h, via priority shipping.

Do you need support? Contact Customer Service or Technical Support.

Online Account
Access or Create Your Account


Regulatory Status

RUO – Research Use Only